The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV M.sup.pro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.

The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV M.sup.pro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.

A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB.sub.1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.

A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB.sub.1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.

Disclosed are compounds having the formula: ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, and methods of making and using the same.

Disclosed are compounds having the formula: ##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, and methods of making and using the same.

Disclosed are compounds having the formula:

##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, and methods of making and using the same.

Disclosed are compounds having the formula:

##STR00001## wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, and methods of making and using the same.

Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (−)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethy lamine, (R)-(−)-2-amino-3-methyl-1-butanol, (−)-cinchonidine, (−)-spartein, (R)-1-naphthylethy lamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and(1R,2S)-(+)-cis-1-amino-2-indanol.

##STR00001##

Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (−)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethy lamine, (R)-(−)-2-amino-3-methyl-1-butanol, (−)-cinchonidine, (−)-spartein, (R)-1-naphthylethy lamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and(1R,2S)-(+)-cis-1-amino-2-indanol.

##STR00001##